Last reviewed · How we verify
adMSC
At a glance
| Generic name | adMSC |
|---|---|
| Sponsor | Paul E Schulz |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Stem Cells for Erectile Dysfunction Post RALP (PHASE1, PHASE2)
- "An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."
- Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury (PHASE1, PHASE2)
- HB-adMSCs for the Treatment of Crohn's Disease (PHASE2)
- Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis (PHASE3)
- Stem Cell Therapy for Early Alzheimer's Disease (PHASE1, PHASE2)
- Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease (PHASE1, PHASE2)
- A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- adMSC CI brief — competitive landscape report
- adMSC updates RSS · CI watch RSS
- Paul E Schulz portfolio CI